During its meeting on July 19-20, 2023, SACHRP advanced its work toward completing one of the recommendations contained in this…
Read More
In mid-2020, against the backdrop of the Black Lives Matter movement and the visibly disparate impact of COVID-19 on racial…
Read More
Some of the most significant changes in the revised Common Rule involve the provisions around informed consent, including the new…
Read MorePRIM&R recently submitted comments in response to the Food and Drug Administration (FDA)’s proposed rule "Institutional Review Board Waiver or…
Read More
On April 19, HHS and 16 other federal agencies released a new Notice of Proposed Rulemaking (NPRM) that would delay the general…
Read More